Guangdong Marubi Biotechnology Co (603983) — Capital Reinvestment Ratio
Guangdong Marubi Biotechnology Co (603983) has a Capital Reinvestment Ratio of 1.31x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥43.25 Million) in capital expenditures (CN¥56.80 Million). See how much free cash does Guangdong Marubi Biotechnology Co generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Guangdong Marubi Biotechnology Co Capital Reinvestment Ratio (2011–2025)
This chart tracks Guangdong Marubi Biotechnology Co's Capital Reinvestment Ratio across 14 annual periods.
Annual Capital Reinvestment Ratio for Guangdong Marubi Biotechnology Co (2011–2025)
Year-by-year Capital Reinvestment Ratio for Guangdong Marubi Biotechnology Co from 2011 to 2025. For live market cap and broader valuation context, see Guangdong Marubi Biotechnology Co (603983) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.75x | CN¥273.88 Million | CN¥205.25 Million | ▼ -28.8% |
| 2024 | 1.05x | CN¥300.53 Million | CN¥316.37 Million | ▲ +40.1% |
| 2023 | 0.75x | CN¥338.02 Million | CN¥254.05 Million | ▼ -67.2% |
| 2022 | 2.29x | CN¥48.44 Million | CN¥110.91 Million | ▲ +10.8% |
| 2020 | 2.07x | CN¥362.35 Million | CN¥748.91 Million | ▲ +14885.7% |
| 2019 | 0.01x | CN¥465.53 Million | CN¥6.42 Million | ▼ -37.2% |
| 2018 | 0.02x | CN¥516.69 Million | CN¥11.34 Million | ▲ +22.4% |
| 2017 | 0.02x | CN¥356.20 Million | CN¥6.39 Million | ▼ -42.2% |
| 2016 | 0.03x | CN¥213.33 Million | CN¥6.62 Million | ▼ -29.3% |
| 2015 | 0.04x | CN¥275.11 Million | CN¥12.08 Million | ▼ -63.0% |
| 2014 | 0.12x | CN¥376.24 Million | CN¥44.63 Million | ▼ -42.4% |
| 2013 | 0.21x | CN¥325.67 Million | CN¥67.10 Million | ▼ -40.9% |
| 2012 | 0.35x | CN¥227.49 Million | CN¥79.34 Million | ▼ -25.2% |
| 2011 | 0.47x | CN¥269.39 Million | CN¥125.59 Million | — |